# 510(k) Summary

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics Operations   
9115 Hague Road   
Indianapolis, IN 46250   
317-521-3831

Contact Person: Corina Harper

Date Prepared: April 2007

# Device name

Proprietary name: cobas c 111 Analyzer

Common name: Analyzer, Chemistry (Photometric, Discrete), for clinical use

Classification name: Discrete photometric chemistry analyzer for clinical use

# Establishment information

The establishment registration number for Roche Diagnostics Ltd. is 3003795116.

The establishment registration number for Roche Diagnostics GmbH is 9610126.

The establishment registration number for Roche Diagnostics Corporation is 1823260.

# Classification

The FDA has classified a discrete photometric analyzer in Class I.   

<table><tr><td>Panel</td><td>Classification Number</td><td>Classification Name</td><td>Regulation Citation</td></tr><tr><td>75 Clinical Chemistry</td><td>1</td><td>Discrete photometric chemistry analyzer for clinical use</td><td>21 CFR 862.2160</td></tr></table>

# 510 Summary, Continued

# Performance standards

To date, no performance standards that affect this device have been finalized under Section 514 of the Act.

# Submission history

The cobas c1 1 1 analyzer is a member of the COBAS INTEGRA $\textsuperscript { \textregistered }$ family of analyzers cleared in the Total Bilirubin reagent submission as K063744. The reagents applied to this analyzer are cleared reagents for the COBAS INTEGRA family of analyzers and were successfully applied to the cobas c 111 analyzer using the Replacement Reagent and Instrument Family Policy  Dec 11, 2003, to demonstrate equivalence to the original reagent/instrument performance.

# Device modification Additional indication for cobas c 111 analyzer

The table below compares the additional intended use for the device, cobas c 111 analyzer to the current device, cobas c 111 for professional use.

<table><tr><td rowspan=1 colspan=1>Topic</td><td rowspan=1 colspan=1>cobas c 111 Analyzerprofessional use(K063744)</td><td rowspan=1 colspan=1>cobas c 111 Analyzerwith extended intendeduse</td></tr><tr><td rowspan=1 colspan=3>Analyzer Description</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indications of Use</td><td rowspan=1 colspan=1>The Roche cobas c 111 analyzer isan in-vitro diagnostic analyzercapable of performing clinicalchemistry, specific protein andelectrolyte tests. Analytes aremeasured photometrically orturbidimetrically; the analyzer alsohas an optional ISE module formeasuring sodium, potassium andchloride.</td><td rowspan=1 colspan=1>The Roche cobas c 111 analyzeris an in-vitro diagnostic analyzercapable of performing clinicalchemistry, specific protein andelectrolyte tests in theprofessional setting and smalllaboratories, specialized testingand CLIA-licensed doctor&#x27;soffices.Analytes are measuredphotometrically orturbidimetrically; the analyzeralso has an optional ISE modulefor measuring sodium,potassium and chloride</td></tr></table>

# 510 Summary, Continued

Device modificationsreagents comparison   

<table><tr><td>Feature</td><td>Reagent performance characteristics on cobas c 111 analyzer for professional use</td><td>Reagent performance characteristics for point-of- care use</td></tr><tr><td>Intended Use for representative reagents</td><td>AST: In vitro test for the quantitative determination of aspartate aminotransferase (AST) in human serum and plasma on the cobas c 111 system. Glucose: In vitro test for the quantitative determination of glucose in human serum and plasma on the cobas c 111 system. CRP: In vitro test for the quantitative determination of C-reactive protein in human serum and plasma on the cobas c 111 system. ISE-C1: The chloride electrode for the cobas e 111 system is intended for the quantitative determination of chloride in diluted serum, plasma and urine. ISE-K: The potassium electrode for the cobas c 111 system is intended for the quantitative determination of chloride in diluted serum, plasma and urine. ISE-Na: The sodium electrode for the cobas c 111 system is intended for the quantitative determination of chloride in diluted serum,</td><td>Same</td></tr><tr><td>Instrument</td><td>plasma and urine. cobas c 111 analyzer</td><td>Same</td></tr><tr><td>Operator Sample type</td><td>Professional setting AST: serum and plasma</td><td>Point-of-care setting Same</td></tr><tr><td></td><td>Glucose: serum and plasma CRP: serum and plasma ISE-Cl: serum, plasma and urine ISE-K: serum, plasma and urine ISE-Na: serum, plasma and urine</td><td></td></tr></table>

The following table compares the panel of six assays performance characteristics on cobas c 111 analyzer for professional use with the point-ofcare use.

Device modifications - reagents comparison (continued)   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Reagent performancecharacteristics on cobas c 111analyzer for professional use</td><td rowspan=1 colspan=1>Reagentperformancecharacteristicsfor point-of-careuse</td></tr><tr><td rowspan=1 colspan=1>Traceability/Standardization</td><td rowspan=1 colspan=1>AST: standardized against the originalIFCC formulation using calibrated pipettestogether with manual photometer providingabsolute values and the substrate-specific absorptivity, éGlucose: standardized against ID/MSCRP: standardized against the referencepreparation of the IRMM  BCR470/CRM470 (RPPHS - Reference Preparationfor Proteins in Human Serum)ISE-Cl/K/Na: standardized against primarycalibrators prepared gravimetrically frompurified salts</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring range</td><td rowspan=1 colspan=1>AST: 2-700 U/LGlucose: 0.11-40 mmol/LCRP: 1-200 mg/LISE-C1: 20-250 mmol/LISE-K: 1-100 mmol/LISE-Na: 20-250 mmol/L</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analyticalsensitivity(LDL)</td><td rowspan=1 colspan=1>AST: 2 U/LGlucose: 0.11 mmol/LCRP: 1.0 mg/LISE-Cl: slope range -25 to -56 mV/decISE-K: slope range 45 to 63 mV/decISE-Na: slope range 45 to 63 mV/dec</td><td rowspan=1 colspan=1>Same</td></tr></table>

Device modifications - reagents comparison (continued)   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Reagent performancecharacteristics on cobas c111 analyzer forprofessional use</td><td rowspan=1 colspan=1>Reagent performancecharacteristics forpoint-of-care use</td></tr><tr><td rowspan=8 colspan=1>PrecisionWithin run(CV%/SD)</td><td rowspan=1 colspan=1>ASTHuman Sera :SD 0.37 at 26.2 U/L0.5% at 221 U/L</td><td rowspan=1 colspan=1>Human sera:SD 0.78 at 18.98 U/L2.07 % at 46.92 U/L</td></tr><tr><td rowspan=1 colspan=1>Controls:1.1% at 39.7 U/L0.4% at 123 U/L</td><td rowspan=1 colspan=1>Controls:1.99% at 41.05 U/L0.63% at 137.93 U/L</td></tr><tr><td rowspan=1 colspan=1>GlucoseHuman Sera:SD 0.5 at 40.9 mg/dL0.8% at 180 mg/dL</td><td rowspan=1 colspan=1>Human sera:0.56% at 89.14 mg/L0.63% at 168.29 mg/L</td></tr><tr><td rowspan=1 colspan=1>Controls:1.0% at 90.6 mg/dL0.5% at 252 mg/dL</td><td rowspan=1 colspan=1>Controls:0.63% at 96.11 mg/L0.66% at 255.47 mg/L</td></tr><tr><td rowspan=1 colspan=1>CRPHuman Sera:SD 0.01 at 0.42 mg/dL1.3% at 23.4 mg/dL</td><td rowspan=1 colspan=1>Human sera:SD 0.072 at 0.356 mg/dL1.15%-- Ot 0.554 mg/dL1.23% at 2.385 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Controls:0.8% at 1.83 mg/dL0.6% at 3.77 mg/dL</td><td rowspan=1 colspan=1>Controls:0.68% at 0.842 mg/dL0.41% at 4.792 mg/dL</td></tr><tr><td rowspan=1 colspan=1>ISE-CIHuman Sera:0.30% at 97 mmol/L0.24% at 1.27 mmol/L</td><td rowspan=1 colspan=1>Human sera:0.72% at 109.03 mmol/L0.72% at 98.55 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Plasma:0.29% at 93 mmol/L0.24% at 124 mmol/L</td><td rowspan=1 colspan=1>Controls:SD 0.43 at 86.22 mmol/L0.54% at 119.04 mmol/L</td></tr></table>

Device modifications - reagents comparison (continued)   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Reagent performancecharacteristics on cobas c111 analyzer forprofessional use</td><td rowspan=1 colspan=1>Reagent performancecharacteristics for point-of-care use</td></tr><tr><td rowspan=4 colspan=1>PrecisionWithin run(CV%)</td><td rowspan=1 colspan=1>ISE - KHuman Sera:0.49% at 2.1 mmol/L0.40% at 5.7 mmol/L</td><td rowspan=1 colspan=1>Human sera:0.79% at 4.65 mmol/L0.71% at 4.69 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Plasma:0.41% at 2.0 mmol/L0.32% at 60. mmol/L</td><td rowspan=1 colspan=1>Controls:0.47% at 3.465 mmol/LSD 0.040 at 6.621 mmol/L</td></tr><tr><td rowspan=1 colspan=1>ISE - NaHuman Sera:0.32% at 130 mmol/L0.31% at 156 mmol/L</td><td rowspan=1 colspan=1>Human sera:0.59% at 144.69 mmol/L0.61% at 133.70 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Plasma0.31% at 127 mmol/L0.30% at 151 mmol/L</td><td rowspan=1 colspan=1>Controls:0.39% at 126.66 mmol/L0.41% at 150.50 mmol/L</td></tr><tr><td rowspan=4 colspan=1>PrecisionTotal(CV%/SD unit)</td><td rowspan=1 colspan=1>ASTHuman Sera:SD 0.64 at 19.5 U/L1.0% at 306 U/L</td><td rowspan=1 colspan=1>Human sera:SD 1.2 at 16.4 U/L3.7% at 48.7 U/L</td></tr><tr><td rowspan=1 colspan=1>Controls:2.4% at 38.6 U/L0.9% at 126 U/L</td><td rowspan=1 colspan=1>Controls:3.3% at 40.24 U/L2.2% at 137.04 U/L</td></tr><tr><td rowspan=1 colspan=1>GlucoseHuman Sera:SD 0.2 at 45.4 mg/dL0.6% at 178 mg/dL</td><td rowspan=1 colspan=1>Human sera:2.6% at 97.5 mg/L2.8% at 130.7 mg/L</td></tr><tr><td rowspan=1 colspan=1>Controls:0.7% at 92.3 mg/dL0.5% at 254 mg/dL</td><td rowspan=1 colspan=1>Controls:2.5% at 93.03 mg/L2.5% at 247.08 mg/L</td></tr></table>

Device modifications - reagents comparison (continued)   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Reagent performancecharacteristics on cobas c111 analyzer forprofessional use</td><td rowspan=1 colspan=1>Reagent performancecharacteristics forpoint-of-care use</td></tr><tr><td rowspan=8 colspan=1>PrecisionTotal(CV%/SD unit)</td><td rowspan=1 colspan=1>CRPHuman Sera:SD 0.01 at 0.47 mg/dL2.6% at 2.33 mg/dL</td><td rowspan=1 colspan=1>Human sera:3.7% at 4.044 mg/dL3.2% at 4.670 mg/L</td></tr><tr><td rowspan=1 colspan=1>Controls:2.1% at 1.86 mg/dL1.6% at 3.84 mg/dL</td><td rowspan=1 colspan=1>Controls:2.6% at 0.835 mg/dL2.9% at 4.764 mg/dL</td></tr><tr><td rowspan=1 colspan=1>ISE - Cl (Between-run)Human sera:0.44% at 97 mmol/L0.48% at 128 mmol/L</td><td rowspan=1 colspan=1>Human sera:1.4% at 104.7 mmol/L1.6% at 104.6 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Plasma (Between-run):0.51% at 93 mmol/L0.67% at 125 mmol/L</td><td rowspan=1 colspan=1>Controls:SD 2.0 at 87.16 mmol/L2.0% at 119.97 mmol/L</td></tr><tr><td rowspan=1 colspan=1>ISE - K (Between -run)Human Sera:0.45% at 2.1 mmol/L0.30% at 5.7 mmol/L</td><td rowspan=1 colspan=1>Human sera:1.4% at 4.465 mmol/L1.6% at 4.540 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Plasma (Between-run)0.78% at 2.0 mmol/L0.72% at 6.0 mmol/L</td><td rowspan=1 colspan=1>Controls:1.8% at 3.466 mmol/LSD 1.8 at 6.646 mmol/L</td></tr><tr><td rowspan=1 colspan=1>ISE - Na (Between-run)Human Sera:0.42% at 130 mmol/L0.48% at 155 mmol/L</td><td rowspan=1 colspan=1>Human sera:1.6% at 139.9 mmol/L1.6% at 131.6 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Plasma:0.80% at 128 mmol/L0.75% at 151 mmol/L</td><td rowspan=1 colspan=1>Controls:1.8% at 126.48 mmol/L1.7% at 151.0 mmol/L</td></tr></table>

Device modifications - reagents comparison (continued)   

<table><tr><td>Feature</td><td>Reagent performance characteristics on cobas c 111 analyzer for professional use AST: Same</td><td>Reagent performance characteristics for point-of-care use</td></tr><tr><td>Limitations - interferences</td><td>Bilirubin- no interference up to I index of 67 (conjugated) and I index of 65 (unconjugated) Hemolysis: elevated results with contamination of erythrocytes Lipemia: interferences Anticoagulants: citrate and fluoride interfere Glucose: Bilirubin— no interference up to I index of 67 (conjugated or unconjugated) Hemolysis: no interference up to H index of 1046 Lipemia: no interference up to L index of 2126 CRP: Bilirubin- no interference up to I index of 60 (conjugated or unconjugated) Hemolysis: no interference up to H index of 700 Lipemia: no interference up to L index of 700 Rheumatoid factors up to 1200 IU/mL do not interfere No high dose hook-effect is seen up to a CRP concentration of 3100 mg/L</td></tr></table>

Device modifications - reagents comparison (continued)   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Reagent performancecharacteristics on cobas c111 analyzer for professionaluse</td><td rowspan=1 colspan=1>Reagent performancecharacteristics forpoint-of-care use</td></tr><tr><td rowspan=1 colspan=1>Limitations -interferences</td><td rowspan=1 colspan=1>ISE-C1:Serum/Plasma:Hemolysis: Avoid hemolyzedsamples. No significantinterferences up to ahemoglobin level of 10 g/LBilirubin/Lipemia: Nosignificant interferencesISE-K:Serum/Plasma:Hemolysis: Avoid hemolyzedsamples. No significantinterferences up to ahemoglobin level of 1 g/L.Potassium centration inerythrocytes is 25 times higherthan in normal plasma. Thelevel of interference may bevariable depending on theexcat content of erythrocytes.Bilirubin/Lipemia: Nosignificant interferencesISE-Na:Serum/Plasma:Hemolysis: Avoid hemolyzedsamples. No significantinterferences up to ahemoglobin level of 10 g/LBilirubin/Lipemia: Nosignificant interferences</td><td rowspan=1 colspan=1>Same</td></tr></table>

Device modifications - reagents comparison (continued)   

<table><tr><td>Feature Endogenous</td><td>Reagent performance characteristics on cobas c 111 analyzer for professional use AST:</td><td>Reagent performance characteristics for point-of-care use</td></tr><tr><td rowspan="5">interferences</td><td rowspan="2">Same No interferences found using common drug panel, except: Doxycycline HCl causes artificially low results Glucose: No interferences found using common drug panel. CRP: No interferences found using ISE-Cl: results Urine:</td></tr><tr><td></td></tr><tr><td>common drug panel. Serum/Plasma: Panel of drugs tested causes no significant interferences Salicylic acid in concentration of 5 mmol/L causes artificially elevated Panel of drugs tested causes no significant interferences, except: Salicylic acid, Ca-dobesilate and Na- cefoxitin which causes artificially</td></tr><tr><td>elevated Cl concentrations ISE-K: Serum/Plasma: Panel of drugs tested causes no significant interferences up to the indicated concentration. Urine: Panel of drugs tested causes no significant interferences up to the indicated concentration.</td><td></td></tr></table>

Device modifications - reagents comparison (continued)   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Reagent performancecharacteristics on cobas c111 analyzer for professionaluse</td><td rowspan=1 colspan=1>Reagent performancecharacteristics forpoint-of-care use</td></tr><tr><td rowspan=1 colspan=1>Endogenousinterferences</td><td rowspan=1 colspan=1>ISE-Na:Serum/Plasma:Panel of drugs tested causes nosignificant interferences up tothe indicated concentration.Urine:Panel of drugs tested causes nosignificant interferences up tothe indicated concentration.pH - Acidified urines can givefalse results.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrationfrequency</td><td rowspan=1 colspan=1>AST/Glucose/CRP:Each lot and as requiredfollowing quality controlproceduresISE-CI/K/Na:24 hours (main calibration)After ISE cleaning andmaintenance, changing reagentbottles, replacing electrodes</td><td rowspan=1 colspan=1>Same</td></tr></table>

Device modifications - reagents comparison (continued)   

<table><tr><td>Feature</td><td>Reagent performance characteristics on cobas c 111 analyzer for professional use</td><td>Reagent performance characteristics for point-of-care use</td></tr><tr><td>Method Comparison Professional use y = cobas c 111 x = Integra 400 Point-of-care use: y = cobas c 111</td><td>AST: Passing Bablok: y = 0.989x + 1.869 U/L τ=0.981 n = 82</td><td>AST: Passing Bablok: y = 0.989x + 1.276 U/L τ = 0.8316 n = 333</td></tr><tr><td>x = Integra 400</td><td>Glucose: y = 1.02x - 0.009 mmol/L τ = 0.983 n = 80</td><td>Glucose: y = 0.997x + 2.069 mg/dL = 0.9217 n =333 CRP:</td></tr><tr><td></td><td>CRP: y = 0.995x + 1.334 mg/L τ = 0.970 n= 63</td><td>y = 1.058x + 0.022 mg/L τ= 0.9789 n = 326 ISE-CI:</td></tr><tr><td></td><td>ISE-CI: y= 1.014x - 3.236 mmol/L r = 0.982 n = 51</td><td>y= 1.011x - 0.51 mmol/L τ = 0.7532 n = 280 ISE-K:</td></tr><tr><td></td><td>ISE-K: y = 0.984x - 0.003 mmol/L r= 1.000 n=51</td><td>y = 0.943x + 0.189 mmol/L τ = 0.8835 n = 280 ISE-Na:</td></tr><tr><td></td><td>ISE-Na: y = 0.986x - 0.364 mmol/L τ = 0.983 n= 51</td><td>y = 1.064x - 9.818 mmol/L τ=0.6920 n = 280</td></tr></table>

Device modifications - reagents comparison (continued)   

<table><tr><td>Feature</td><td>Reagent performance characteristics on cobas c 111 analyzer for professional use</td><td>Reagent performance characteristics for point-of-care use</td></tr><tr><td>Expected values (from reference) (also please reference method sheet)</td><td>AST: Female: up to 32 U/L Males: up to 38 U/L Glucose:</td><td>Same</td></tr><tr><td></td><td>Plasma fasting: 3.88-6.38 mmol/L Serum/Plasma Adults: 4.11-5.89 mmol/L CRP:</td><td></td></tr><tr><td></td><td>Adults: less than 5 mg/L ISE-C1: Serum/Plasma (adults): 98-107 mmol/L</td><td></td></tr><tr><td></td><td>Urine (24h, adults): 110-250 mmol/L ISE-K: Serum (adults): 3.5-5.1 mmol/L Plasma (adults): 3.4-4.5 mmol/L</td><td></td></tr><tr><td>Plasma (adults): 136-145 mmol/L Urine (24h, adults): 40-220 mmol/L</td><td>Urine (24h, adults) 25-125 mmol/L ISE-Na: Serum (adults): 136-145 mmol/L</td><td></td></tr></table>

Roche Diagnostics Corporation   
c/o Corina Harper, Regulatory Affairs Consultant   
9115 Hague Road   
Indianapolis, IN 46250

# JUL 3 0 2007

Re: k071211 Trade/Device Name: cobas c 111 analyzer and applied reagents Regulation Number: 21 CFR 862.1100 Regulation Name: Aspartate amino transferase (AST/SGO) test system Regulatory Class: Class II Product Code: CIT, CFR, DCN, CEM, CGZ, JGS, JJE Dated: April 30, 2007 Received: May 1, 2007

Dear Ms. Harper:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have beercassif rdance wih the rovisions  the Federal FoDr and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M.Coopes, M.S. D.V.M. Jean M. Cooper, M.S., D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number (if known):_ K071211

Device Name: cobas c 111 analyzer and applied reagents

Indications For Use:

# cobas c 111 analyzer:

The Roche cobas c 111 analyzer is an in-vitro diagnostic analyzer capable of performing clinical chemistry, specific protein and electrolyte tests for professional settings and small laboratories, specialized testing and CLIA-licensed doctor's offices.

Analytes are measured photometrically or turbidimetrically; the analyzer also has an optional ISE module for measuring sodium, potassium and chloride.

# Reagents:

Aspartate aminotransferase (ASTL/ASTPL)

In vitro test for the quantitative determination of AST in human serum and plasma on the cobas c111 system. Aspartate amino transferase measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

# Indications for Use

510(k) Number (if known): K071211

Device Name: cobas c 111 analyzer and reagents

Indications For Use:

C-Reactive Protein Latex (CRPLX)   
In vitro test for the quantitative immunological determination of human C-reactive protein in human serum and plasma on the cobas c111 system. Measurement of C-reactive protein aids in evaluation of the amount of injury to body tissues.

Glucose HK (GLUC2)

In vitro test for the quantitative determination of glucose concentration in human serum and plasma on the cobas cl 1 1 system. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus and idiopathic hypoglycemia.

ISE Chloride Electrode

The chloride electrode for the cobas cl11 system is intended for the quantitative determination of chloride in diluted serum, plasma, and urine. Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis.

# Indications for Use

510(k) Number (if known): K071211

Device Name: cobas c 111 analyzer and reagents

Indications For Use:

ISE Potassium Electrode

The potassium electrode for the cobas c111 system is intended for the quantitative determination of potassium in diluted serum, plasma; and urine. Measurements of potassium are used to monitor electrolyte balance in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels.

ISE Sodium Electrode

The sodium electrode for the cobas c111 system is intended for the quantitative determination of sodium in diluted serum, plasma, and urine. Measurements of sodium are used in the diagnosis and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypernsion,Adison' seas (causedby destructio the drenalglands)dehydrati, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance.